Francesca Gilli, PhD, Dartmouth College, Hanover, NH, discusses the exciting research focused on inhibiting the C1q component, which serves as an activating factor for the classical complement pathway. Preclinical data indicates a significant reduction in overall complement pathway activation, inflammation, and neurodegenerative damage such as demyelination and neuronal damage in the brain. This promising approach has the potential to lead to the development of a therapeutic strategy to inhibit this specific pathway. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
